Slowakije - Slowaaks - ŠÚKL (Štátny ústav pre kontrolu liečiv)

teva pharmaceuticals slovakia s.r.o., slovensko - fulvestrant - 34 - antihormona

Slowakije - Slowaaks - ŠÚKL (Štátny ústav pre kontrolu liečiv)

ever valinject gmbh, rakúsko - fulvestrant - 34 - antihormona

Slowakije - Slowaaks - ŠÚKL (Štátny ústav pre kontrolu liečiv)

accord healthcare polska sp. z o.o., poľsko - fulvestrant - 34 - antihormona

Slowakije - Slowaaks - ŠÚKL (Štátny ústav pre kontrolu liečiv)

fresenius kabi s.r.o., Česká republika - fulvestrant - 34 - antihormona

Europese Unie - Slowaaks - EMA (European Medicines Agency)

sanofi pasteur - neisseria meningitidis group c polysaccharide conjugated to tetanus toxoid, neisseria meningitidis group a polysaccharide conjugated to tetanus toxoid, neisseria meningitidis group y polysaccharide conjugated to tetanus toxoid, neisseria meningitidis group w-135 polysaccharide conjugated to tetanus toxoid - meningitída, meningokoková - vakcíny - menquadfi is indicated for active immunisation of individuals from the age of 12 months and older against invasive meningococcal disease caused by neisseria meningitidis serogroups a, c, w, and y. the use of this vaccine should be in accordance with available official recommendations.

Slowakije - Slowaaks - ŠÚKL (Štátny ústav pre kontrolu liečiv)

vipharm s.a., poľsko - fulvestrant - 34 - antihormona

Europese Unie - Slowaaks - EMA (European Medicines Agency)

accord healthcare s.l.u. - cabazitaxel - prostatic neoplasms, kastrácia-odolný - antineoplastické činidlá - treatment of patients with hormone refractory metastatic prostate cancer previously treated with a docetaxel-containing regimen.

Slowakije - Slowaaks - ŠÚKL (Štátny ústav pre kontrolu liečiv)

glenmark pharmaceuticals s.r.o., Česká republika - fulvestrant - 34 - antihormona

Europese Unie - Slowaaks - EMA (European Medicines Agency)

amgen europe bv - sotorasib - karcinóm, pľúc bez malých buniek - antineoplastické činidlá - lumykras as monotherapy is indicated for the treatment of adults with advanced non-small cell lung cancer (nsclc) with kras g12c mutation and who have progressed after at least one prior line of systemic therapy.

Europese Unie - Slowaaks - EMA (European Medicines Agency)

midas pharma gmbh - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; diabetes complications - oftalmologiká - ranivisio is indicated in adults for:• the treatment of neovascular (wet) age-related macular degeneration (amd)• the treatment of visual impairment due to diabetic macular oedema (dme)• the treatment of proliferative diabetic retinopathy (pdr)• the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)• the treatment of visual impairment due to choroidal neovascularisation (cnv).